A Study to Evaluate the Safety and Immunogenicity of a Single Dose of Adsorbed Tetanus Vaccine in a Population Aged 18 Years and Over

NCT06123663 | Completed Phase 1

• 1 other identifier: CTP-TTVA-001
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups, Subjects who gave informed consent and passed the questioning screen were randomly assigned 1:1 to be immunized with 1 dose of Tetanus Vaccine, Adsorbed (TTVA) or control vaccine.

Conditions

Tetanus

Keywords

Vaccine; Positive-controlled; Safety; ≥18 years

Outcome Measures

Primary Outcomes (1)

• Incidence of adverse reactions (AR) in subjects

  0-30 days after immunization

Secondary Outcomes (5)

• Incidence of AR

  30 minutes after immunization

• Incidence of adverse events (AE)

  0-30 days after immunization

• Incidence of AR/AE

  0-7 days post-immunization

• Proportion of laboratory safety indicators with clinically significant changes (CS), including hemoglobin level (HGB), white blood cell count (WBC), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL)

  Day 8 post-immunization

• Incidence of serious adverse events (SAEs)

  6 months post-immunization

Study Arms (2)

Tetanus Vaccine, Adsorbed (TTVA)

EXPERIMENTAL

1 dose of (TTVA) (0.5ml)

Biological: TTVA

Tetanus Vaccine, Adsorbed (TT)

ACTIVE COMPARATOR

1 dose of (TT) (0.5ml)

Biological: TT

Interventions

TTVA BIOLOGICAL

Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0

Tetanus Vaccine, Adsorbed (TTVA)

TT BIOLOGICAL

Intramuscular injection, 1 dose of 0.5ml inoculated on Day 0

Tetanus Vaccine, Adsorbed (TT)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• years of age and older, able to provide valid proof of identity for himself/herself.
• Ability to understand the requirements and process of the study and to agree to participate in the clinical trial and to sign an informed consent form.
• Ability to comply with the requirements of the clinical trial protocol and complete all follow-up studies.

You may not qualify if:

• Previously diagnosed tetanus infection.
• Vaccination against tetanus or vaccines containing tetanus toxoid antigen components (e.g., DPT, DPT, RCV, etc.) within 5 years.
• Axillary temperature \>37.0°C on the day of enrollment.
• Women with a positive urine pregnancy test or during pregnancy or breastfeeding.
• Women of childbearing age, male volunteers and male volunteers whose partner is a woman of childbearing age have a pregnancy plan or birth plan during the study period.
• Persons suffering from thrombocytopenia, any coagulation disorder, or receiving anticoagulant therapy that may contraindicate intramuscular injection.
• Suffering from serious respiratory diseases, serious cardiovascular diseases, liver and kidney diseases, malignant tumors, serious infectious or allergic skin diseases, hypertension that cannot be controlled by medication (at the time of on-site measurement: systolic blood pressure ≥160mmHg, diastolic blood pressure ≥100mmHg), and being in the period of acute disease or chronic disease activity within 7 days.
• History of severe neurological disorders such as epilepsy, convulsions, encephalopathy, or history of psychiatric disorders.
• Previous history of severe allergy to vaccination or medication (anaphylaxis, anaphylactic laryngeal edema, anaphylactic purpura, thrombocytopenic purpura, localized anaphylactic necrotic reaction (Arthus reaction), etc.).
• Allergy to certain components of the vaccine used in this clinical trial (mainly tetanus toxoid, aluminum hydroxide, sodium chloride, etc.) or allergy to the above components from previous vaccination.
• Known or suspected immunological abnormalities (e.g., HIV infection, history of thyroid, pancreas, liver, spleen, kidney disease or resection), immunosuppressive therapy, cytotoxic therapy, systemic glucocorticosteroid medication (≥14 days) within 6 months prior to enrollment (excluding spray corticosteroid therapy for allergic rhinitis, surface corticosteroid therapy for acute uncomplicated dermatitis, etc.) topical medications).
• Received blood products (whole blood, component blood, immune globulin, etc.) in the previous 3 months or plan to use such products within 1 month of vaccination.
• Vaccination with live attenuated vaccine within 14 days, subunit vaccine or inactivated vaccine within 7 days.
• Plans to participate or is participating in clinical studies of any other drug.
• Abnormalities in preimmunization blood counts and blood biochemistry that are judged by the investigator to be clinically significant.

Sponsors & Collaborators

• CanSino Biologics Inc.: lead

Study Sites (1)

Center for Disease Control and Prevention, Qixingguan District, Bijie City

Bijie, Guizhou, China

Location

MeSH Terms

Conditions

Tetanus

Condition Hierarchy (Ancestors)

Clostridium Infections; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Study Officials

• Shiguang Lei

  Guizhou Center for Disease Control and Prevention

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 1, 2023
• First Posted: November 9, 2023
• Study Start: December 20, 2023
• Primary Completion: January 23, 2024
• Study Completion: June 18, 2024
• Last Updated: November 29, 2024

Record last verified: 2023-10

Locations

CN (1)